# Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

> **NCT01132313** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 488 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** BI 207127
- **DRUG:** BI 201335
- **DRUG:** BI 207127
- **DRUG:** BI 201335
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin
- **DRUG:** BI 207127
- **DRUG:** BI 207127
- **DRUG:** BI 207127
- **DRUG:** BI 201335
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin
- **DRUG:** BI 207127
- **DRUG:** BI 207127
- **DRUG:** BI 201335
- **DRUG:** BI 201335
- **DRUG:** Ribavirin
- **DRUG:** BI 201335
- **DRUG:** BI 201335

## Key facts

- **NCT ID:** NCT01132313
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2016-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132313, "Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01132313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*